VANCOUVER, BC--(Marketwired - October 17, 2017) - Cannabis Wheaton Income Corp. ( TSX VENTURE : CBW ) ("Cannabis Wheaton"or"CBW") and Beleave Inc. ( CSE : BE ) ( OTCQX : BLEVF ) ("Beleave" or the "Company") are pleased to announce that, further to the news release dated October 5, 2017, CBW has provided an initial advance of $5,000,000 in non-dilutive debt financing by way of an instrument evidencing a debt obligation repayable in product equivalents (the "D.O.P.E. Note"). As previously announced, the proceeds of the D.O.P.E Note will be used by Beleave to fund the construction of an expansion facility, to be situated adjacent to Beleave's current facility outside of Hamilton, Ontario.

ON BEHALF OF THE BOARD

"Chuck Rifici"

Chairman & CEO

About Cannabis Wheaton Income Corp. ( TSX VENTURE : CBW )

Backed by a team of industry experts, Cannabis Wheaton is the first cannabis streaming company in the world. Our streams will include production from across Canada coming from our partners comprised of licensed producers of cannabis (LP) and LP applicants. Cannabis Wheaton's mandate is to facilitate real growth for our streaming partners by providing them with financial support and sharing our collective industry experience.

Stay Connected

For more information about Cannabis Wheaton and our management team, please visit: http://www.cannabiswheaton.com, or follow us on Twitter @CannabisWheaton. Call: 1.604.687.7130 Email: mario@skanderbegcapital.com www.skanderbegcapital.com.

About Beleave Inc. ( CSE : BE )

Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located near Hamilton, Ontario.

Forward-Looking Information

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the D.O.P.E. Note being paid back in full or at all, the ability to enforce against the D.O.P.E. Note in the event of default, the ability to generate revenue through the streaming agreements, the ability to consummate transactions which are currently in discussions, requirements to obtain additional financing, timeliness of government approvals for granting of permits and licences, including licences to cultivate and sell cannabis, completion of the facilities, where applicable, actual operating performance of the facilities, regulatory or political change, competition and other risks affecting CBW or Beleave in particular and the medical cannabis industry generally. There is no assurance that any further advances under the D.O.P.E. Note will be made, nor that the parties will proceed to funding under the interim streaming agreement. Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Neither CBW nor Beleave is under any obligation, and each expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.